Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Avalo Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 66 | 84 | +18 |
| Shares | 15.3M | 19.9M | +4.57M (+29.8%) |
| Value | $194.7M | $361.1M | +$166.4M (+85.5%) |
New holders (33)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
Sold out (15)
Institutions that held Avalo Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Ally Bridge Group (NY) LLC | 178,100 | $2.26M |
| Deep Track Capital, LP | 144,600 | $1.84M |
| Exome Asset Management LLC | 100,036 | $1.27M |
| Adviser Investments LLC | 86,516 | $1.10M |
| Cantor Fitzgerald, L. P. | 85,247 | $1.08M |
| DLD Asset Management, LP | 75,000 | $953.3K |
| Landscape Capital Management, L.L.C. | 33,337 | $423.7K |
| ADAR1 Capital Management, LLC | 32,393 | $411.7K |
| Birchview Capital, LP | 31,000 | $394.0K |
| Prelude Capital Management, LLC | 24,628 | $313.0K |
| Dimensional Fund Advisors LP | 11,215 | $143.2K |
| BIT Capital GmbH | 1,929 | $24.5K |
| Simplex Trading, LLC | 748 | $9.00K |
| SBI Securities Co., Ltd. | 23 | $292 |
| Avion Wealth | 5 | $0 |